# 119-hr-5467: PAAT Act

119-hr-5467, PAAT Act, is a 119th Congress bill sponsored by Rep. Johnson, Julie [D-TX-32] (D-TX); status introduced; PRIA reads it as touching household money (as of 2026-04-21).

- Canonical: https://policyrisk.com/legislation/119-hr-5467
- As of: 2026-04-21
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Bill: 119-hr-5467
- Congress: 119
- Title: PAAT Act
- Status: introduced
- Introduced: 2025-09-18
- Sponsor: Rep. Johnson, Julie [D-TX-32] (D-TX)
- Cosponsors: 5
- Policy area: Health
- Touches household money: yes
- Last recorded action: 2026-04-21

## Summary

**Would require Medicare Part D plans to cover drugs for autoimmune diseases and certain blood disorders and limit how often prior authorization can be required.** This bill would amend the Social Security Act so that, beginning in 2027, Prescription Drug Plan (PDP) sponsors must include on their formularies any Part D drug that is indicated and prescribed for an autoimmune disease, hemophilia, or Von Willebrand disease. It would also restrict prior authorization for those drugs so plans may not demand it more than once in any 12-month period, with explicit exceptions. - Medicare beneficiaries with autoimmune conditions, hemophilia, or Von Willebrand disease would see their Part D plans required to list their prescribed drugs on formularies, improving the baseline availability of these treatments. - Prescription Drug Plan sponsors and Medicare Advantage prescription drug (MA-PD) organizations would have to add these drugs and could not require prior authorization more than once every 12 months, except for drugs typically used 12 months or less, opioids, benzodiazepines, barbiturates, carisoprodol, or drugs subject to a FDA risk evaluation and mitigation strategy. - Clinicians and pharmacies would face fewer repeated prior-authorization requests for these therapies because plans are limited in how often they can reauthorize treatment in a year.

## Cosponsors (5)

- Rep. Kennedy, Mike [R-UT-3] (R-UT), 2025-09-18T00:00:00.000Z
- Rep. Elfreth, Sarah [D-MD-3] (D-MD), 2025-10-10T00:00:00.000Z
- Rep. Cleaver, Emanuel [D-MO-5] (D-MO), 2025-10-17T00:00:00.000Z
- Del. Norton, Eleanor Holmes [D-DC-At Large] (D-DC), 2025-11-19T00:00:00.000Z
- Rep. Gottheimer, Josh [D-NJ-5] (D-NJ), 2025-11-19T00:00:00.000Z

## Provisions PRIA read

- Easier Medicare drug access for autoimmune and blood disorders: benefit, medium. Starting in 2027, Medicare Part D plans would have to list all covered drugs used to treat autoimmune diseases, hemophilia, and Von Willebrand disease. This would apply to stand‑alone Part D plans and to Medicare Advantage plans with drug coverage. Plans could not make you get prior authorization m…

## Related bills

- 119-hr-9877: Health Equity and Accountability Act of 2026
- 119-hr-7973: Momnibus Act
- 119-hr-1262: Mikaela Naylon Give Kids a Chance Act
- 119-hr-7853: PrEP Access and Coverage Act of 2026
- 119-hr-5862: American Energy Independence and Affordability Act
- 119-hr-2048: Metastatic Breast Cancer Access to Care Act

## Sources
- [119-hr-5467 on Congress.gov](https://www.congress.gov/bill/119th-congress/house-bill/5467)

## Related
- [119-hr-9877: Health Equity and Accountability Act of 2026](https://policyrisk.com/legislation/119-hr-9877)
- [119-hr-7973: Momnibus Act](https://policyrisk.com/legislation/119-hr-7973)
- [119-hr-1262: Mikaela Naylon Give Kids a Chance Act](https://policyrisk.com/legislation/119-hr-1262)
- [119-hr-7853: PrEP Access and Coverage Act of 2026](https://policyrisk.com/legislation/119-hr-7853)
- [119-hr-5862: American Energy Independence and Affordability Act](https://policyrisk.com/legislation/119-hr-5862)
- [119-hr-2048: Metastatic Breast Cancer Access to Care Act](https://policyrisk.com/legislation/119-hr-2048)
- [All bills in Congress](https://policyrisk.com/legislation)

Source: PRIA, https://policyrisk.com/legislation/119-hr-5467 (as of 2026-04-21).